Liothyronine

Limits on what this shows

• Key negative/null findings: None found directly refuting T3-driven mitochondrial biogenesis; the mechanism is consistently replicated across animal/cell literature.
• At-risk subgroups: Over-replacement/suppressive dosing; patients with pre-existing cardiac or skeletal muscle mitochondrial vulnerability.
• Counter-evidence on record: The same biogenesis pathway is the basis for T3's therapeutic benefit in hypothyroid patients (restoring normal mitochondrial density and metabolic rate); it is not inherently harmful at replacement dosing.

Regulatory status

Not addressed in the Cytomel label as a mitochondrial-specific warning.

Population evidence

Tier B, T3-specific: Weitzel et al. 2003, review, "thyroid hormone (T3) has a profound effect on mitochondrial biogenesis" [4]; Costilla et al. 2019, animal (Balb/c mice), T3-induced experimental hyperthyroidism increased oxidative stress with compensatory Nrf2-mediated antioxidant transcription in lymphoid tissue [8]. No human liothyronine-arm mitochondrial-structure data identified.

Mechanism

Named: T3 binds nuclear thyroid receptors regulating mitochondrial biogenesis genes (e.g., PGC-1alpha pathway) and increases oxidative phosphorylation capacity and mitochondrial number/density.

Counter-evidence held on record

Shares its underlying mechanism and one source (Costilla et al. 2019) with the Oxidative stress and ATP production entries below; see Overlap map. Not a nutrient-supplementable finding.

Limits on what this shows

• Key negative/null findings: Baskol et al. 2007 found oxidative stress markers were elevated in untreated hypothyroidism and improved with thyroid hormone treatment, an outcome running counter to a simple "thyroid hormone causes oxidative stress" narrative; direction depends on baseline thyroid status and dose.
• At-risk subgroups: Over-replacement/thyrotoxic-range exposure specifically, not replacement-dose therapy of hypothyroidism.
• Counter-evidence on record: See null finding above; the relationship is bidirectional and dose/baseline-dependent, not a monotonic depletion signal.

Regulatory status

Not addressed in the Cytomel label.

Population evidence

Tier B: Costilla et al. 2019, animal, T3-induced hyperthyroid Balb/c mice, increased oxidative stress markers with Nrf2-driven antioxidant enzyme transcription in lymphoid tissue [8]. Tier C/context: Baskol et al. 2007, human, oxidative stress and antioxidant enzyme status improved after treatment of hypothyroidism (opposite direction, treatment with thyroid hormone normalizing rather than worsening oxidative markers in that specific cohort) [9]; Mancini et al. 2016, review of thyroid hormone, oxidative stress, and inflammation generally.

Mechanism

Named: increased mitochondrial oxidative phosphorylation flux from T3 excess raises reactive oxygen species generation, triggering compensatory Nrf2-pathway antioxidant enzyme upregulation.

Counter-evidence held on record

Shares its animal source with the Mitochondrial burden entry (see Overlap map). Applies only to excess/thyrotoxic exposure, not to correctly dosed replacement therapy.

Limits on what this shows

• Key negative/null findings: Urinary copper excretion was not significantly different from controls, arguing against a renal-wasting mechanism specifically.
• At-risk subgroups: Endogenous or iatrogenic thyrotoxic-range exposure; data are from Graves'-type disease populations, confounded by autoimmune disease itself (Hard confounding-by-indication caveat).
• Counter-evidence on record: None found suggesting copper deficiency in thyroid hormone excess; all located human data point the opposite direction (elevation).

Regulatory status

Not addressed in the Cytomel label.

Population evidence

Tier C, endogenous disease, not liothyronine-specific: Aihara et al. 1984, Am J Clin Nutr, human, hyperthyroid vs hypothyroid vs control patients: "plasma and erythrocyte [copper] concentrations significantly above normal in hyperthyroidism"; urinary copper not significantly different [10].

Mechanism

Not firmly established in the source; plausibly related to ceruloplasmin as a hepatic acute-phase-like protein upregulated under the hypermetabolic state, rather than a specific copper-handling defect.

Counter-evidence held on record

This is an excess-direction finding. Do not use it to justify copper supplementation, and do not let it be relabeled as "copper depletion" on any consumer-facing surface; that would invert the actual evidence. Shares its single source with Zinc and Selenium below (see Overlap map).

Limits on what this shows

• Key negative/null findings: None of the located microbiome studies isolate thyroid hormone exposure from Graves' autoimmunity; this is recorded as a limitation, not resolved.
• At-risk subgroups: Cannot be specified with confidence given the confounding; theoretically, patients with marked hypermotility/diarrhea on over-replacement.
• Counter-evidence on record: Confounding by indication (Hard Rule 6) is presumed, not excluded, for every located human microbiome study; none used a euthyroid-on-liothyronine vs. untreated comparison that would isolate the drug's effect from the autoimmune disease.

Regulatory status

Increased GI motility/diarrhea is a listed adverse effect of thyroid hormone excess in the Cytomel label [1], though the label does not address microbiome composition.

Population evidence

Tier C, disease-state, not drug-specific: Chang et al. 2021, Chen et al. 2021, Biscarini et al. 2023 (INDIGO study), and related observational studies all describe altered gut microbiota composition in Graves' disease patients, but these cohorts are defined by autoimmune Graves' disease, not by liothyronine or any exogenous thyroid hormone exposure; no study administering T3/liothyronine and measuring microbiome composition was located despite multiple search phrasings across PubMed hosts.

Mechanism

Named (established pharmacology, mechanism G/H): thyroid hormone excess accelerates GI transit time and motility, a known route to altered microbial composition independent of autoimmunity.

Counter-evidence held on record

The motility mechanism is real and drug-relevant; the composition data is not drug-specific and is heavily confounded by autoimmune thyroid disease. Present only as a theoretical/mechanism flag.

Limits on what this shows

• Key negative/null findings: None identified directly refuting the uncoupling mechanism; it is well replicated across the mechanistic literature. No clinical outcome data (e.g., measured ATP deficit symptoms) were found for liothyronine users at therapeutic dose.
• At-risk subgroups: Patients on over-replacement or suppressive-dose liothyronine (e.g., thyroid cancer TSH suppression protocols, T3 add-on therapy above physiologic need).
• Counter-evidence on record: At physiologic replacement dosing, the same mechanism restores normal ATP-linked respiration in hypothyroid tissue; the effect is dose-dependent and bidirectional, not a one-way "depletion."

Regulatory status

Not addressed as a nutrient/energy warning in the Cytomel label; the underlying thermogenic mechanism of thyroid hormone is standard endocrine pharmacology.

Population evidence

Tier B mechanistic literature using T3 directly: Yau et al. 2019 (cell/animal, autophagy-mediated mitochondrial turnover with T3-stimulated fatty acid oxidation) [3]; Schönfeld et al. 1997 (animal, T3-induced ADP/ATP carrier expression and uncoupling) [5]; Gregory & Berry 1992 (T3 stimulation of coupled respiration and ATP synthesis in isolated hepatocytes) [6]; Harper & Seifert 2008 (review of thyroid hormone mitochondrial energetics) [7]. No human liothyronine-arm trial directly measuring ATP synthesis efficiency was found.

Mechanism

Named: T3 upregulates uncoupling-protein and adenine-nucleotide-carrier pathways, diverting proton-motive force to heat rather than ATP synthesis (thermogenesis); this is the drug's intended action at physiologic replacement and becomes a burden only at supraphysiologic exposure.

Counter-evidence held on record

This is a mechanism-level, dose-dependent effect of the drug's own pharmacology, not a nutrient the patient is losing. No supplement addresses mitochondrial uncoupling; the corrective action is dose titration to the lowest effective dose, done by a prescriber.

Limits on what this shows

• Key negative/null findings: Anemia is reported in both hypo- and hyperthyroidism in the literature via different, sometimes opposing mechanisms (erythropoietin stimulation vs. dilutional/autoimmune effects), so no single consistent direction can be asserted; this is recorded rather than resolved into a simple claim.
• At-risk subgroups: Cannot be specified with confidence; data are heterogeneous across endogenous hyper- and hypothyroid populations.
• Counter-evidence on record: Mixed-direction findings above constitute internal counter-evidence against any single clean claim.

Regulatory status

Not addressed in the Cytomel label as a hematologic warning.

Population evidence

Tier C, endogenous disease and mixed models: Santosh et al. 2025, human prospective study, thyroid hormones stimulating erythropoietin gene expression in the context of anemia across hypo- and hyperthyroidism [18]; Kjaergaard et al. 2022, Mendelian randomization, low-normal T3 linked to macrocytic anemia patterns (a genetic/observational association, not an interventional T3 study) [19]. Cell-level, T3-specific but in vitro: PubMed search listings also identified Yamamoto et al. 2014 (PMID 24604674) and Shiraishi et al. 2015 (PMID 25787723), both describing T3 modulating erythroid differentiation in K562 cells; these could not be opened for full-text confirmation during this review and are noted here as titles only, not relied on for the grade.

Mechanism

Named: thyroid hormone upregulates erythropoietin gene expression and oxygen consumption, which can independently raise (via EPO stimulation) or complicate (via increased plasma volume/dilution, or via associated autoimmune disease) hemoglobin and hematocrit values.

Counter-evidence held on record

Evidence is genuinely mixed in direction; do not present as a clean "thyroid hormone causes anemia" or "improves oxygenation" claim in either direction.